Akers Biosciences Announces Conference Call to Discuss Q2 2016 Earnings
August 09 2016 - 11:00AM
Marketwired
Akers Biosciences Announces Conference Call to Discuss Q2 2016
Earnings
THOROFARE, NJ-(Marketwired - Aug 9, 2016) - Akers Biosciences,
Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a
developer of rapid health information technologies, will hold a
conference call on Thursday, August 11, 2016 at 09:00 a.m. Eastern
Time to discuss its earnings for the second quarter ended June 30,
2016, which will be published earlier that day. Management will be
available during a question-and-answer session.
To participate in the call from within the U.S., please dial
1-888-417-8465 approximately 10 minutes prior to the scheduled
start time. International callers should dial 1-719-325-2499. The
Conference ID is 5673717. Interested parties can also listen via a
live Internet webcast, which can be found at
https://public.viavid.com/index.php?id=120809
A recording of the call will be available in the Investor Center
of the Company's website at
http://www.akersbio.com/investor-center.
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:Akers Biosciences, Inc.Raymond F. Akers,
Jr. PhDCo-founder and Chief Scientific DirectorTel. +1 856 848
8698Taglich Brothers, Inc. (Investor Relations)Chris SchreiberTel.
+1 917 445 6207Email: cs@taglichbrothers.comfinnCap (UK Nominated
Adviser and Broker)Adrian Hargrave / Scott Mathieson (Corporate
Finance)Steve Norcross (Broking)Tel. +44 (0)20 7220 0500Vigo
Communications (Public Relations)Ben Simons / Fiona HensonTel. +44
(0)20 7830 9700Email: akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Apr 2023 to Apr 2024